Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Pfizer

The biotech industry has a reputation for being a breeding ground for high-value mergers and acquisitions, which does not come as a surprise given the aggressive push by leading biotech companies to consolidate their market position. Seagen Inc. ( SGEN , Financial), a biotech company that develops therapies for cancer treatment, has been the target of several large players in the industry.

Pfizer Is Eyeing a Deal With Seagen After Merck's Failure

Pfizer Inc. has been reported as bidding for Seagen Inc., competing with Merck & Co., Inc. for the cancer drug company. Seagen analysts forecast booming sales on FDA approvals of multiple cancer drugs.

Pfizer Needs The Seagen Deal

Biopharma giant Pfizer is eyeing an acquisition of Seagen, the Seattle area's biggest biotech company, according to a report in the Wall Street Journal Monday.

Seagen stock rises as Pfizer reportedly in talks to acquire Seattle-area biotech giant

Seagen (NASDAQ: SGEN ) stock is up about 11% and is one of the top-trending tickers on reports that the drug maker could be acquired by Pfizer (NYSE: PFE ) for over $30 billion. The negotiations are just starting and may not result in a deal.

The $30 Billion Reason Seagen (SGEN) Stock Is Up 11% Today

Seagen Inc (NASDAQ: SGEN) opened more than 10% up this morning on reports that Pfizer Inc (NYSE: PFE) is interested in buying the cancer therapies company.

Seagen stock opened 13% up on Monday: find out why

Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday. The post 'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover appeared first on Investor's Business Daily.

'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover

Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.

Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ

Pfizer Inc (NYSE:PFE) is reportedly in talks to buy Seagen Inc (Seattle Genetics, Inc. (NASDAQ:SGEN)), a cancer drug maker that was last year tied to a potential takeover by Merk before negotiations broke down. Seagen shares shot up some 13% in pre-market deals to trade at US$182.99 following a Wall Street Journal report on Sunday claiming early-stage takeover talks were underway, citing ‘people familiar with the matter'.

Seagen stock jumps on Pfizer takeover talk

Pfizer is in early talks to acquire cancer drugmaker Seagen in a potentially multibillion-dollar deal, The Wall Street Journal reported Monday.

Seagen's stock surges 15% after a report that Pfizer is in talks to buy the cancer-focused biotech

Li Auto Inc.

The stock market looked poised to climb on Monday morning.

Li Auto Powers Up, but Another Stock Is Really Stepping on the Gas

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen's website at investor.seagen.com.

Seagen to Present at the Cowen 43rd Annual Health Care Conference

Union Pacific

Here are some of the most active stocks in the premarket on Monday. U.S. stock futures ES00, +0.50% were pointing to an advance after the worst week for the S&P 500 SPX, -1.05% since the period that ended Dec. 9.

Seagen's stock soars on reported Pfizer buyout interest; Union Pacific shares rally after CEO ouster

The deal would strengthen Pfizer's lineup of cancer treatments, The Wall Street Journal reports.

Pfizer in Talks to Buy Seagen for $30 Billion or More

Pfizer Inc is in early talks to acquire drugmaker Seagen Inc , the Wall Street Journal reported late on Sunday, citing people familiar with the matter.

Pfizer in talks to buy Seagen for likely for more than $30 bln - WSJ

Pfizer Inc. is in talks to acquire biotech Seagen Inc, according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies.

Pfizer in Early-Stage Talks to Acquire Seagen

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.

Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up

Alkermes

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared. The post Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out appeared first on Investor's Business Daily.

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out

Seagen Inc. (NASDAQ:SGEN ) Q4 2022 Results Conference Call February 15, 2023 4:30 PM ET Company Participants Doug Maffei - VP, IR David Epstein - CEO Chip Romp - EVP, Commercial U.S. Todd Simpson - CFO Roger Dansey - President, R&D Conference Call Participants Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Jessica Fye - JP Morgan Jay Olson - Oppenheimer Steven Willey - Stifel Gregory Renza - RBC Capital Markets Yige Guo - Guggenheim Securities Andy Hsieh - William Blair Joe Catanzaro - Piper Sandler Andrew Berens - SVB Securities Dane Leone - Raymond James Operator Good day everyone and welcome to the Seagen Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions] Please also note, today's event is being recorded.

Seagen Inc. (SGEN) Q4 2022 Earnings Call Transcript

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its potentially transformative oncology pipeline.

Seagen Reports Fourth Quarter and Full Year 2022 Financial Results

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of new data featuring PADCEV® (enfortumab vedotin-ejfv) at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) taking place from February 16-18, 2023. A podium presentation will feature noteworthy patient-reported outcomes from the registrational Phase 1b/2 EV‐103 Cohort K study.

Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for

Allogene Therapeutics Inc

Editas Medicine

Intellia Therapeutics

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication

BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA's Accelerated Approval Program based on tumor response rate and durability of response from the phase 2 MOUNTAINEER clinical trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This is the first FDA-approved treatment in HER2-positive metastatic colorectal cancer. The FDA previously granted Breakthrough Therapy Designation and Priority Review for TUKYSA in this setting.

Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer

News for Seagen Stock (SGEN)